Oracle Applications Framework up to 12.2.15 Web Utilities privilege escalation
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.7 | $5k-$25k | 1.31 |
Summary
A vulnerability categorized as problematic has been discovered in Oracle Applications Framework up to 12.2.15. Affected is an unknown function of the component Web Utilities. The manipulation results in privilege escalation. This vulnerability is cataloged as CVE-2026-62546. The attack may be launched remotely. There is no exploit available.
Details
A vulnerability classified as problematic has been found in Oracle Applications Framework up to 12.2.15. Affected is an unknown functionality of the component Web Utilities. The manipulation with an unknown input leads to a privilege escalation vulnerability. This is going to have an impact on confidentiality, integrity, and availability. CVE summarizes:
Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Web Utilities). Supported versions that are affected are 12.2.8-12.2.15. Easily exploitable vulnerability allows high privileged attacker with network access via HTTP to compromise Oracle Applications Framework. While the vulnerability is in Oracle Applications Framework, attacks may significantly impact additional products (scope change). Successful attacks of this vulnerability can result in takeover of Oracle Applications Framework. CVSS 3.1 Base Score 9.1 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H).
The advisory is available at oracle.com. This vulnerability is traded as CVE-2026-62546 since 07/14/2026. The exploitability is told to be easy. It is possible to launch the attack remotely. Additional levels of successful authentication are needed for exploitation. The technical details are unknown and an exploit is not available. The structure of the vulnerability defines a possible price range of USD $5k-$25k at the moment (estimation calculated on 07/22/2026).
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
If you want to get best quality of vulnerability data, you may have to visit VulDB.
Product
Vendor
Name
Version
- 12.2.0
- 12.2.1
- 12.2.2
- 12.2.3
- 12.2.4
- 12.2.5
- 12.2.6
- 12.2.7
- 12.2.8
- 12.2.9
- 12.2.10
- 12.2.11
- 12.2.12
- 12.2.13
- 12.2.14
- 12.2.15
License
Website
- Vendor: https://www.oracle.com
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.7VulDB Meta Temp Score: 4.7
VulDB Base Score: 4.7
VulDB Temp Score: 4.7
VulDB Vector: 🔒
VulDB Reliability: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Privilege escalationCWE: Unknown
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
07/14/2026 CVE reserved07/22/2026 Advisory disclosed
07/22/2026 VulDB entry created
07/22/2026 VulDB entry last update
Sources
Vendor: oracle.comAdvisory: oracle.com
Status: Confirmed
CVE: CVE-2026-62546 (🔒)
GCVE (CVE): GCVE-0-2026-62546
GCVE (VulDB): GCVE-100-382194
Entry
Created: 07/22/2026 09:03Changes: 07/22/2026 09:03 (51)
Complete: 🔍
Cache ID: 216::103
If you want to get best quality of vulnerability data, you may have to visit VulDB.
No comments yet. Languages: en.
Please log in to comment.